脉冲式静脉卵泡刺激素治疗对肥胖女性卵巢功能的影响
前瞻性干预研究纳入27名正常体重和27名肥胖的月经规律女性,在早期卵泡期进行两天频繁采血,比较西曲瑞克抑制促性腺激素前后及外源脉冲式静脉重组卵泡刺激素(rFSH)给药后的抑制素B和雌二醇(E2)水平。肥胖女性基础抑制素B和E2降低且对FSH刺激反应显著减弱,BMI与二者呈负相关;但脉冲式静脉rFSH使肥胖女性E2和抑制素B达到与正常体重女性无外源FSH刺激时相当的水平。结论认为脉冲式FSH可部分纠正肥胖相关的相对低促性腺激素性性腺功能减退。
要点
- 改良促性腺激素释放激素拮抗方案有效抑制正常及高BMI女性内源性促性腺激素。
- 肥胖女性基础抑制素B和E2降低,对FSH刺激反应显著减弱,BMI与二者负相关。
- 脉冲式静脉rFSH使肥胖女性E2和抑制素B达正常体重女性无外源FSH刺激时水平。
核心结论
- 尽管外源静脉给药使FSH水平和脉冲性正常化,肥胖女性仍表现出E2和抑制素B分泌方面的卵巢功能障碍。
- 脉冲式FSH可部分纠正肥胖相关的相对低促性腺激素性性腺功能减退,从而提供一种潜在治疗策略以减轻高BMI对生育、辅助生殖和妊娠结局的部分不良影响。
研究设计与样本
- 前瞻性干预研究,在学术医疗中心进行。
- 纳入27名正常体重女性和27名肥胖女性,均为月经规律、年龄21-39岁。
- 干预为早期卵泡期两天频繁采血研究,在西曲瑞克抑制促性腺激素前后及外源脉冲式静脉重组卵泡刺激素(rFSH)给药后进行。
- 主要结局指标为血清抑制素B和雌二醇(E2)水平(基础及rFSH刺激后)。
- 临床试验注册号:ClinicalTrials.gov #NCT02478775。
主要发现
- 改良促性腺激素释放激素拮抗方案有效抑制正常和高BMI女性内源性促性腺激素产生。
- 静脉rFSH治疗在正常体重和肥胖女性中产生等效的血清水平和药效学。
- 肥胖女性基础抑制素B和E2水平降低,对FSH刺激反应显著减弱。
- BMI与血清抑制素B和E2呈负相关。
- 脉冲式静脉rFSH使肥胖女性E2和抑制素B水平达到与正常体重女性无外源FSH刺激时相当的水平。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To establish conditions for effective hypothalamic suppression in women with normal and high body mass index (BMI) and test the hypothesis that intravenous (IV) administration of pulsatile recombinant follicle-stimulating hormone (rFSH) can overcome the clinically evident dysfunctional pituitary-ovarian axis in women with obesity. DESIGN: Prospective interventional study. SETTING: Academic medical center. PATIENT(S): Twenty-seven normal-weight women and 27 women with obesity, who were eumenorrheic and aged 21-39 years. INTERVENTION(S): Two-day frequent blood sampling study, in early follicular phase, before and after cetrorelix suppression of gonadotropins and exogenous pulsatile IV rFSH administration. MAIN OUTCOME MEASURE(S): Serum inhibin B and estradiol (E2) levels (basal and rFSH stimulated). RESULT(S): A modified gonadotropin-releasing hormone antagonism protocol effectively suppressed production of endogenous gonadotropins in women with normal and high BMIs, providing a model to address the functional role of FSH in the hypothalamic-pituitary-ovarian axis. The IV rFSH treatment resulted in equivalent serum levels and pharmacodynamics in normal-weight women and those with obesity. However, women with obesity exhibited reduced basal levels of inhibin B and E2 and a significantly decreased response to FSH stimulation. The BMI was inversely correlated with serum inhibin B and E2. In spite of this observed deficit in ovarian function, pulsatile IV rFSH treatment in women with obesity resulted in E2 and inhibin B levels comparable with those in normal-weight women, in the absence of exogenous FSH stimulation. CONCLUSION(S): Despite normalization of FSH levels and pulsatility by exogenous IV administration, women with obesity demonstrate ovarian dysfunction with respect to E2 and inhibin B secretion. Pulsatile FSH can partially correct the relative hypogonadotropic hypogonadism of obesity, thereby providing a potential treatment strategy to mitigate some of the adverse effects of high BMI on fertility, assisted reproduction, and pregnancy outcomes. CLINICAL TRIAL REGISTRATION NUMBER: ClinicalTrials.gov #NCT02478775.
引用
- Luu TH, Kuhn K, Bradford AP, et al. Effects of pulsatile intravenous follicle-stimulating hormone treatment on ovarian function in women with obesity. Fertil Steril. 2023. PMID: 37276947. doi:10.1016/j.fertnstert.2023.05.170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。